TheraRadar
Data updated: May 26, 2026

Vonvendi (von willebrand factor (recombinant))

Approved 2015-12-07
1
Indication
--
Phase 3 Trials
10
Years on Market

Details

Status
Prescription
First Approved
2015-12-07
Patent Cliff
2029

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
Intravenous
Dosage Forms
For Injection

Vonvendi Approval History

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2015 to 2015
Dec 2015 ORIGINAL
Update · CBER biologic (Purple Book)

What Vonvendi Treats

1 FDA approvals

Originally approved for its first indication in 2015 .

  • Other (1)
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT07129343 TAK-577-3002 Ph 3 recruiting A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
NCT02973087 results posted 071301 2016-001478-14 Ph 3 completed rVWF IN PROPHYLAXIS
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

Vonvendi FDA Label Details

Track Vonvendi with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.